We are live on
!
Find out more
Neurocrine Biosciences
NBIX
NBIX
694 hedge funds and large institutions have $13.1B invested in Neurocrine Biosciences in 2026 Q1 according to their latest regulatory filings, with 83 funds opening new positions, 302 increasing their positions, 216 reducing their positions, and 109 closing their positions.
New
Increased
Maintained
Reduced
Closed
40% more repeat investments, than reductions
Existing positions increased: 302 | Existing positions reduced: 216
0.09% more ownership
Funds ownership: 99.49% → 99.58% (+0.09%)
5% less funds holding
Funds holding: 730 → 694 (-36)
6% less capital invested
Capital invested by funds: $14.1B → $13.1B (-$913M)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
24% less first-time investments, than exits
New positions opened: 83 | Existing positions closed: 109
43% less call options, than puts
Call options by funds: $39.1M | Put options by funds: $69M
Holders
694
Holders Change
-36
Holders Change %
-4.93%
% of All Funds
8.55%
Holding in Top 10
8
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-20%
% of All Funds
0.1%
New
83
Increased
302
Reduced
216
Closed
109
Calls
$39.1M
Puts
$69M
Net Calls
-$30M
Net Calls Change
+$349K
Top Buyers
| 1 |
Two Sigma Investments
New York
|
+$275M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$221M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$166M |
| 4 |
Millennium Management
New York
|
+$107M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$80.5M |
